Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 17/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031597 | 0.83 | SLC2A1 (0.52) | TP53 | |
| SCHEMBL14031559 | 0.82 | SLC2A1 (0.43) | TP53TSHRHTTCKS1BSKP1 | |
| SCHEMBL5067678 | 0.82 | RPS6KA5 (0.47) | TP53KDM4EALDH1A1TSHRHTT | |
| SCHEMBL5058432 | 0.77 | CKS1B (0.39) | TSHRHTTCKS1BSKP1SKP2 | |
| SCHEMBL5058527 | 0.77 | CKS1B (0.39) | TSHRHTTCKS1BSKP1SKP2 | |
| SCHEMBL4070921 | 0.77 | SMN1; SMN2 (0.39) | KDM4EALDH1A1TSHRHTTHSD17B10 | |
| SCHEMBL4069078 | 0.76 | RPS6KA5 (0.46) | TP53KDM4EALDH1A1TSHRHTT | |
| SCHEMBL14031568 | 0.74 | RPS6KA5 (0.47) | TP53KDM4EALDH1A1TSHRHTT | |
| SCHEMBL4071929 | 0.73 | RPS6KA5 (0.55) | TP53 | |
| SCHEMBL4070786 | 0.73 | SLC2A1 (0.39) | ALDH1A1MDM2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | TP53 37/4885KDM4E 1693/4885ALDH1A1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.